Skip To Main Content
Giovanni Mori on Muck Rack

Giovanni Mori

Italy
As seen in: LIFEGATE, Nature, Wiley Online Library, MDPI, Domani, Journal of Infection
Ing energetico, datemi 'na mano a salvare il mondo TEDx su soluzioni climatiche youtu.be/Xteb_iHPM8Q ⬇️ Faccio un podcast ogni mattina per LifeGate
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Giovanni

Contact Giovanni, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Rezafungin Utilisation in Real Life-FungiScope Results From Europe and the United States

|
By Ilana Reinhold, Giovanni Mori, Massimiliano Lanzafame, Alessandro Limongelli
| Wiley Online Library Verified
1 Introduction Invasive candidiasis (IC) and candidemia remain life-threatening infections, particularly in critically ill and immunocompromised patients. Successful management has been complicated by the shift of Candida albicans to non-albicans species over the past decade, including Candida glabrata (Nakaseomyces glabratus), Candida parapsilosis, and Candida auris [1]. Echinocandins remain the first-line antifungal for IC, whereby treatment requires daily intravenous (i.v.) administration [2].
Open in Who Shared Issue with article?

Risk stratification and impact of donor type on breakthrough invasive fungal infections in haematopoietic cell transplant with post-transplant cyclophosphamide and mould-active prophylaxis | Bone Marrow Transplantation

|
By Francesca Farina, Giovanni Mori, Sara Mastaglio, Simona Piemontese, Fabio Ciceri, Raffaella Greco, Andrea Acerbis
| Nature Verified
Abstract Incidence of breakthrough proven-probable invasive fungal infections (b-PP-IFIs) in allogeneic haematopoietic cell transplant recipients (allo-HCT-r) receiving mould-active prophylaxis (MAP) and post-transplant cyclophosphamide (PT-Cy) is largely unknown.
Open in Who Shared Issue with article?

Advances in HIV Treatment: Long-Acting Antiretrovirals and the Path Toward a Cure

|
By Massimiliano Lanzafame, Giovanni Mori, Sandro Vento
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?
See all 9 articles